User Fees, Biomedical Overhaul, Elections: FDA Braces For The Crash
This article was originally published in The Tan Sheet
Executive Summary
Negotiating new user fee deal with industry will be difficult without knowing scope of agency’s new responsibilities from pending reform legislation, acting FDA chief Ostroff notes, but shape of that bill itself may depend on next elections.